广泛期小细胞肺癌-话题@MedSci

#广泛期小细胞肺癌#

24篇内容 | 1108人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1350184, encodeId=5f5213501843a, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=2022 ASCO：恶病质对广泛期小细胞肺癌患者一线免疫治疗疗效的影响, objectType=article, longId=728259, objectId=88dde28259a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88dde28259a8, replyNumber=0, likeNumber=34, createdTime=2022-06-01, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88dde28259a8, moduleTitle=2022 ASCO：恶病质对广泛期小细胞肺癌患者一线免疫治疗疗效的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88dde28259a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350185, encodeId=061313501850f, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=2022 ASCO：对复发性或难治性广泛期小细胞肺癌患者连续服用他拉唑帕尼（TALA）加间歇性低剂量替莫唑胺（TMZ）的2期研究, objectType=article, longId=728258, objectId=3b8ae28258e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b8ae28258e7, replyNumber=0, likeNumber=33, createdTime=2022-06-01, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b8ae28258e7, moduleTitle=2022 ASCO：对复发性或难治性广泛期小细胞肺癌患者连续服用他拉唑帕尼（TALA）加间歇性低剂量替莫唑胺（TMZ）的2期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b8ae28258e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350183, encodeId=180213501830e, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=2022 ASCO：PD-L1抑制剂联合EP作为一线疗法对广泛期小细胞肺癌伴有脑转移的的疗效, objectType=article, longId=728252, objectId=27bce282523d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27bce282523d, replyNumber=0, likeNumber=58, createdTime=2022-06-01, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27bce282523d, moduleTitle=2022 ASCO：PD-L1抑制剂联合EP作为一线疗法对广泛期小细胞肺癌伴有脑转移的的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27bce282523d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350182, encodeId=e286135018293, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=Lancet Oncol：Adebrelimab联合化疗一线治疗广泛期小细胞肺癌, objectType=article, longId=727377, objectId=ce1ee2737728, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce1ee2737728, replyNumber=0, likeNumber=38, createdTime=2022-05-21, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce1ee2737728, moduleTitle=Lancet Oncol：Adebrelimab联合化疗一线治疗广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce1ee2737728)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350181, encodeId=4312135018131, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=Tiragolumab联合阿替利珠单抗治疗广泛期小细胞肺癌的III期研究，结果失败（SKYSCRAPER-02研究）, objectType=article, longId=302277, objectId=26843022e794, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26843022e794, replyNumber=0, likeNumber=0, createdTime=2022-04-04, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26843022e794, moduleTitle=Tiragolumab联合阿替利珠单抗治疗广泛期小细胞肺癌的III期研究，结果失败（SKYSCRAPER-02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26843022e794)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350180, encodeId=483b135018029, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=朱慧教授：广泛期小细胞肺癌的放射治疗, objectType=article, longId=294126, objectId=fe99294126e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe99294126e8, replyNumber=0, likeNumber=35, createdTime=2022-01-19, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe99294126e8, moduleTitle=朱慧教授：广泛期小细胞肺癌的放射治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe99294126e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350179, encodeId=001213501e980, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=Thorac Cancer：广泛期小细胞肺癌(ED-SCLC)患者标准一线化疗治疗后使用阿帕替尼维持治疗可进一步延长生存, objectType=article, longId=294109, objectId=be7a294109e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be7a294109e3, replyNumber=0, likeNumber=60, createdTime=2022-01-18, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be7a294109e3, moduleTitle=Thorac Cancer：广泛期小细胞肺癌(ED-SCLC)患者标准一线化疗治疗后使用阿帕替尼维持治疗可进一步延长生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be7a294109e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350178, encodeId=f61613501e8c5, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=Front Oncol：广泛期小细胞肺癌（ED-SCLC）患者治疗结局：来自韩国9994例患者回顾性分析结果, objectType=article, longId=218713, objectId=d3a7218e136e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3a7218e136e, replyNumber=0, likeNumber=32, createdTime=2021-10-18, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3a7218e136e, moduleTitle=Front Oncol：广泛期小细胞肺癌（ED-SCLC）患者治疗结局：来自韩国9994例患者回顾性分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3a7218e136e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350177, encodeId=a2a613501e7fe, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=J Thorac Oncol：尼拉帕利一线维持治疗中国铂敏感的广泛期小细胞肺癌患者的3期临床试验结果, objectType=article, longId=210730, objectId=22a4210e30f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22a4210e30f6, replyNumber=0, likeNumber=39, createdTime=2021-05-03, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22a4210e30f6, moduleTitle=J Thorac Oncol：尼拉帕利一线维持治疗中国铂敏感的广泛期小细胞肺癌患者的3期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22a4210e30f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350176, encodeId=f6d713501e6a9, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=JTO：Rova-T联合纳武单抗或伊匹单抗治疗广泛期小细胞肺癌的疗效和安全性, objectType=article, longId=207873, objectId=e3af20e873d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3af20e873d7, replyNumber=0, likeNumber=37, createdTime=2021-03-06, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3af20e873d7, moduleTitle=JTO：Rova-T联合纳武单抗或伊匹单抗治疗广泛期小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3af20e873d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350175, encodeId=0eb513501e521, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle= J Clin Oncol：卡铂/依托泊苷方案+阿妥珠单抗作为广泛期小细胞肺癌一线治疗方案的延长随访预后结果（IMpower133试验）, objectType=article, longId=205905, objectId=050d20590572, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=050d20590572, replyNumber=0, likeNumber=40, createdTime=2021-01-21, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=050d20590572, moduleTitle= J Clin Oncol：卡铂/依托泊苷方案+阿妥珠单抗作为广泛期小细胞肺癌一线治疗方案的延长随访预后结果（IMpower133试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=050d20590572)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350174, encodeId=e09a13501e42f, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=Lancet oncology| 广泛期小细胞肺癌一线Durvalumab联合治疗的效果比较, objectType=article, longId=205265, objectId=52e920526519, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52e920526519, replyNumber=0, likeNumber=41, createdTime=2021-01-05, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52e920526519, moduleTitle=Lancet oncology| 广泛期小细胞肺癌一线Durvalumab联合治疗的效果比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52e920526519)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350173, encodeId=2a2513501e331, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=Clin Lung Cancer：Atezolizumab可有效治疗日本广泛期小细胞肺癌患者，且耐受性良好, objectType=article, longId=201761, objectId=5d9d201e6149, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d9d201e6149, replyNumber=0, likeNumber=28, createdTime=2020-10-07, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d9d201e6149, moduleTitle=Clin Lung Cancer：Atezolizumab可有效治疗日本广泛期小细胞肺癌患者，且耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d9d201e6149)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350172, encodeId=7aa613501e2f9, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=欧盟批准Imfinzi（durvalumab）一线治疗广泛期小细胞肺癌, objectType=article, longId=200402, objectId=25b120040271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25b120040271, replyNumber=0, likeNumber=37, createdTime=2020-09-09, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25b120040271, moduleTitle=欧盟批准Imfinzi（durvalumab）一线治疗广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25b120040271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350171, encodeId=446513501e150, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=PD-L1单抗Imfinzi在日本获批，治疗广泛期小细胞肺癌, objectType=article, longId=199855, objectId=787719985534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=787719985534, replyNumber=0, likeNumber=42, createdTime=2020-08-24, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=787719985534, moduleTitle=PD-L1单抗Imfinzi在日本获批，治疗广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=787719985534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350170, encodeId=1b1d13501e091, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗, objectType=article, longId=191241, objectId=eff619124151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eff619124151, replyNumber=0, likeNumber=31, createdTime=2020-04-03, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eff619124151, moduleTitle=FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eff619124151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350169, encodeId=d460135016988, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=喜讯！罗氏的Tecentriq在中国获得批准，用于治疗广泛期小细胞肺癌, objectType=article, longId=188190, objectId=a74718819031, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a74718819031, replyNumber=0, likeNumber=27, createdTime=2020-02-17, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a74718819031, moduleTitle=喜讯！罗氏的Tecentriq在中国获得批准，用于治疗广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a74718819031)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350168, encodeId=b472135016805, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌, objectType=article, longId=185527, objectId=8ca718552e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ca718552e25, replyNumber=0, likeNumber=33, createdTime=2020-01-03, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ca718552e25, moduleTitle=因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ca718552e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350167, encodeId=3844135016e4e, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=一线治疗显著改善广泛期小细胞肺癌患者的总生存期, objectType=article, longId=181036, objectId=bfa3181036ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfa3181036ef, replyNumber=0, likeNumber=27, createdTime=2019-10-14, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfa3181036ef, moduleTitle=一线治疗显著改善广泛期小细胞肺癌患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfa3181036ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350166, encodeId=75ac1350166b0, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, objectTitle=研究全面解析：广泛期小细胞肺癌免疫+化疗再传捷报, objectType=article, longId=180795, objectId=8de3180e95ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8de3180e95ac, replyNumber=0, likeNumber=27, createdTime=2019-10-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8de3180e95ac, moduleTitle=研究全面解析：广泛期小细胞肺癌免疫+化疗再传捷报, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8de3180e95ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

广泛期小细胞肺癌

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

2022 ASCO：恶病质对广泛期小细胞肺癌患者一线免疫治疗疗效的影响

2022-06-01

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

2022 ASCO：对复发性或难治性广泛期小细胞肺癌患者连续服用他拉唑帕尼（TALA）加间歇性低剂量替莫唑胺（TMZ）的2期研究

2022-06-01

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

2022 ASCO：PD-L1抑制剂联合EP作为一线疗法对广泛期小细胞肺癌伴有脑转移的的疗效

2022-06-01

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

Lancet Oncol：Adebrelimab联合化疗一线治疗广泛期小细胞肺癌

2022-05-21

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

Tiragolumab联合阿替利珠单抗治疗广泛期小细胞肺癌的III期研究，结果失败（SKYSCRAPER-02研究）

2022-04-04

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

朱慧教授：广泛期小细胞肺癌的放射治疗

2022-01-19

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

Thorac Cancer：广泛期小细胞肺癌(ED-SCLC)患者标准一线化疗治疗后使用阿帕替尼维持治疗可进一步延长生存

2022-01-18

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

Front Oncol：广泛期小细胞肺癌（ED-SCLC）患者治疗结局：来自韩国9994例患者回顾性分析结果

2021-10-18

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

J Thorac Oncol：尼拉帕利一线维持治疗中国铂敏感的广泛期小细胞肺癌患者的3期临床试验结果

2021-05-03

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

JTO：Rova-T联合纳武单抗或伊匹单抗治疗广泛期小细胞肺癌的疗效和安全性

2021-03-06

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

J Clin Oncol：卡铂/依托泊苷方案+阿妥珠单抗作为广泛期小细胞肺癌一线治疗方案的延长随访预后结果（IMpower133试验）

2021-01-21

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

Lancet oncology| 广泛期小细胞肺癌一线Durvalumab联合治疗的效果比较

2021-01-05

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

Clin Lung Cancer：Atezolizumab可有效治疗日本广泛期小细胞肺癌患者，且耐受性良好

2020-10-07

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

欧盟批准Imfinzi（durvalumab）一线治疗广泛期小细胞肺癌

2020-09-09

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

PD-L1单抗Imfinzi在日本获批，治疗广泛期小细胞肺癌

2020-08-24

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗

2020-04-03

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

喜讯！罗氏的Tecentriq在中国获得批准，用于治疗广泛期小细胞肺癌

2020-02-17

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌

2020-01-03

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

一线治疗显著改善广泛期小细胞肺癌患者的总生存期

2019-10-14

zhaojie88 (审核中...)

前往app查看评论内容

#广泛期小细胞肺癌#

研究全面解析：广泛期小细胞肺癌免疫+化疗再传捷报

2019-10-11

科室
- - 订阅+
  - 更多科室
工具
服务